Backed by:
Team
Sacha Schermerhorn
CEO / Founder
Laura Remesal, PhD
Founding Scientist
John Macor, PhD
Diligence Team (Chemistry)
Bill Greenlee, PhD
Diligence Team (Chemistry)
Dario Doller, PhD
Discovery Team (Chemistry)
Ben Buller, PhD
Discovery Team (Pharmacology)
Andy Ambrose, PhD
Discovery Team (Chemical Biology)
Richard Libby, PhD
Portfolio Team (Risk / Capital)
Pat Weber, PhD
Diligence Team (Structural Biology)
Eric Parker, PhD
Diligence Team (Pharmacology)
Jim MacDonald, PhD
Diligence Team (Toxicology)
Catherine Strader, PhD
Diligence Team (Drug Development)
Mike Rowley, PhD, FRSC
Diligence Team (Chemistry)
Our team is responsible for:
46
FDA approved medicines
650+
patents
3
ACS Med Chem Hall of Farmers
210+
Clinical candidates
$78B
in total acquisitions
Drugs our team previously discovered:
3rd
most prescribed drug in USA
Lisinopril is a an angiotensin-converting enzyme (ACE) inhibitor and used to treat hypertension, heart failure, and heart attacks. For high blood pressure it is usually a first-line treatment. Lisinopril is also used to prevent kidney problems in people with diabetes mellitus. The drug ranks as the third most prescribed drug in the U.S., with 82.5 million prescriptions in 2022. Developed by Merck and approved in 1987.
Learn More
Bill Greenlee, PhD
1
2
3
4
Advisory Board
Steve Holtzman
Business Development
Michelle Arkin, PhD
Chemistry
Matt Krisiloff
Operations / Fundraising
Made in Webflow